Buprenorphine and Integrated HIV Care

Completed · Phase 4

Conditions studied: Substance-related Disorders, Drug Addiction, Human Immunodeficiency Virus, AIDS, HIV Infections

In brief

The purpose of this study is to examine the efficacy of providing two levels of psychosocial support along with buprenorphine/naloxone (BUP) maintenance to opioid dependent patients receiving their care in an HIV clinical care setting.

Key facts

Study ID

NCT00317460

Run by

Yale University

People needed

52

Starts

2005-09-01

Expected to finish

2012-10-01

Last updated by the study team

2020-04-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV disease
• DSM-IV criteria for opioid dependence, as assessed by SCID
• Documented opioid positive urine toxicology testing

You may not qualify if…

• Desire to remain enrolled in opioid agonist treatment at an opioid treatment program
• Current dependence on alcohol, benzodiazepines or sedatives (patients who are receiving benzodiazepines under the care of a psychiatrist for the treatment of an anxiety disorder will not be excluded)
• Current suicide or homicide risk
• Current psychotic disorder or major depression
• Inability to read or understand English
• Dementia
• Life-threatening or unstable medical problems requiring inpatient medical care or nursing home placement
• Currently enrolled in other studies involving the provision of psychosocial treatment.

Where it is running

• Yale University School of Medicine — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.